Open Access

COMMENTARY

SULING XU¹, XIAO LI², WENXUE MA^3,*
Oncology Research, Vol.32, No.11, pp. 1701-1708, 2024, DOI:10.32604/or.2024.055161 - 16 October 2024
（This article belongs to the Special Issue: Pharmacological Bases of Anticancer Drug Therapies in Precision Oncology)
Abstract The environment surrounding a tumor, known as the tumor microenvironment (TME), plays a role in how cancer progresses and responds to treatment. It poses both challenges and opportunities for improving cancer therapy. Recent progress in understanding the TME complexity and diversity has led to approaches for treating cancer. This perspective discusses the strategies for targeting the TME, such as adjusting networks using extracellular vesicles to deliver drugs and enhancing immune checkpoint inhibitors (ICIS) through combined treatments. Furthermore, it highlights adoptive cell transfer (ACT) therapies as an option for tumors. By studying how components of the More >

View

644

Download

152

Open Access

ARTICLE

SHAIL RAKESH MODI, TERRICK ANDEY^*
Oncology Research, Vol.32, No.11, pp. 1709-1721, 2024, DOI:10.32604/or.2024.053972 - 16 October 2024
Abstract Objectives: EGFR tyrosine kinase inhibitor (EGFR-TKI) therapies such as erlotinib and gefitinib are approved for the treatment of non-small cell lung cancer (NSCLC). However, the high incidence of acquired resistance to these EGFR-TKIs may preclude their effectiveness. Piperlongumine (PPL), an extract from the long pepper fruit (Piper longum), has been shown to possess anticancer properties. The purpose of the study was to investigate piperlongumine as an anticancer agent and to study a combination treatment approach with EGFR-TKIs against lung cancer cells. Methods: Anticancer efficacy of PPL, erlotinib (ERL), gefitinib (GEF), and cisplatin (CIS) were investigated in… More >

View

810

Download

179

Open Access

ARTICLE

JEN-PIN CHUANG^1,2,3, HSIANG-LIN TSAI^4,5, WEI-CHIH SU^4,6,7, PO-JUNG CHEN^4,6, CHING-WEN HUANG^4,5, TSUNG-KUN CHANG^4,6,7, YEN-CHENG CHEN^4,6, CHING-CHUN LI^4,8, YUNG-SUNG YEH^4,9,10, TZU-CHIEH YIN^4,5,11, JAW-YUAN WANG^{4,5,6,12,13,*}
Oncology Research, Vol.32, No.11, pp. 1723-1732, 2024, DOI:10.32604/or.2024.052098 - 16 October 2024
Abstract Background: The pTNM staging system is widely recognized as the most effective prognostic indicator for cancer. The latest update of this staging system introduced a new pathological staging system (ypTNM) for patients receiving neoadjuvant chemoradiotherapy (NACRT). However, whether the prognostic value of the ypTNM staging system for rectal cancer is similar to that of the pTNM staging system remains unclear. This study was conducted to compare the ypTNM and pTNM staging systems in terms of their prognostic value for patients with nonmetastatic rectal cancer undergoing proctectomy. Material and Methods: This study was conducted at a large teaching… More >

View

644

Download

128

Open Access

ARTICLE

RONG LIU^1,#, SHENG LI^2,#, SITU XIONG², FUCUN ZHENG², XIANGPENG ZHAN², JIN ZENG², BIN FU², SONGHUI XU², SHAOXING ZHU^1,*, RU CHEN^1,*
Oncology Research, Vol.32, No.11, pp. 1733-1746, 2024, DOI:10.32604/or.2024.050851 - 16 October 2024
Abstract EVI2A has emerged as a significant biomarker in various diseases; however, its biological role and mechanism in kidney renal clear cell carcinoma (KIRC) remains unexplored. We used TCGA and GEO databases to analyze EVI2A gene expression comprehensively and performed pan-cancer assessments. Clinical relevance was evaluated through Kaplan-Meier analysis and ROC curves. The gene’s immune relevance was explored through analyses of the tumor microenvironment (TME), Tumor Immune Single-cell Hub (TISCH), immune checkpoints, and immunotherapy sensitivity. Our results indicate that EVI2A expression is upregulated in KIRC, showing correlations with tumor grade and T/N/M stage. EVI2A demonstrates high… More >

View

1027

Download

183

Open Access

ARTICLE

YE ZHANG¹, YANAN LIANG², YAN WU², LIWEN SONG², ZUWANG ZHANG^2,*
Oncology Research, Vol.32, No.11, pp. 1747-1763, 2024, DOI:10.32604/or.2024.030945 - 16 October 2024
Abstract Background: Papillary thyroid cancer (PTC) is the most prevalent histological type of differentiated thyroid malignancy. Circular RNAs (circRNAs) have been implicated in the pathogenesis and progression of various cancers. circTIAM1 (hsa_circ_0061406) is a novel circRNA with aberrant expression in PTC. However, its functional roles in PTC progression remain to be investigated. Methods: The expression levels of circTIAM1 in the PTC and the matched para-cancerous tissues were detected by quantitative real-time reverse-transcription PCR (qRT-PCR). The subcellular localization of circTIAM1 was examined by fluorescence in-situ hybridization (FISH). Kaplan-Meier plot was used to analyze the association of clinicopathological features… More >

View

937

Download

192

Open Access

ARTICLE

YONGJIAN HUANG, JINZHOU WANG, JIUHUA XU, NING RUAN^*
Oncology Research, Vol.32, No.11, pp. 1765-1776, 2024, DOI:10.32604/or.2024.045564 - 16 October 2024
Abstract Background: Despite significant advancements in the development of anticancer therapies over the past few decades, the clinical management of colorectal cancer remains a challenging task. This study aims to investigate the inhibitory effects of cancer-targeting liposomes against colorectal cancer. Materials and Methods: Liposomes consisting of 3β-[N-(N′, N′-dimethylamino ethane)carbamoyl]-cholesterol (DC-CHOL), cholesterol (CHOL), and dioleoylphosphatidylethanolamine (DOPE) at a molar ratio of 1:1:0.5 were created and used as carriers to deliver an apoptosis-inducing plasmid encoding the tumor necrosis factor-related apoptosis-inducing ligand (pTRAIL) gene, along with the toll-like receptor (TLR7) agonist Rsiquimod (R848). The rationale behind this design is that More >

Graphic Abstract

View

797

Download

139

Open Access

ARTICLE

LICHEN XU^1,2, PAN ZHANG^3,*, GUIQI ZHANG², ZHAOLIANG SHEN⁴, XIZHUANG BAI^1,3,*
Oncology Research, Vol.32, No.11, pp. 1777-1789, 2024, DOI:10.32604/or.2024.047704 - 16 October 2024
Abstract Background: Osteosarcoma (OS), recognized as the predominant malignant tumor originating from bones, necessitates an in-depth comprehension of its intrinsic mechanisms to pinpoint novel therapeutic targets and enhance treatment methodologies. The role of fat mass and obesity-associated (FTO) in OS, particularly its correlation with malignant traits, and the fundamental mechanism, remains to be elucidated. Materials and Methods: 1. The FTO expression and survival rate in tumors were analyzed. 2. FTO in OS cell lines was quantified utilizing western blot and PCR. 3. FTO was upregulated and downregulated separately in MG63. 4. The impact of FTO on the… More >

View

811

Download

160

Open Access

ARTICLE

JINXIA CHEN^1,2,3,#, SULI DAI^1,2,#, GENG ZHANG^4,5, SISI WEI^1,2, XUETAO ZHAO³, YANG ZHENG^1,2, YAOJIE WANG^1,2, XIAOHAN WANG^1,2, YUNJIANG LIU^4,5,*, LIANMEI ZHAO^1,2,*
Oncology Research, Vol.32, No.11, pp. 1791-1802, 2024, DOI:10.32604/or.2024.049348 - 16 October 2024
（This article belongs to the Special Issue: Recent Advances in Cancer Pharmacology)
Abstract Background: Triple-negative breast cancer (TNBC) is a heterogeneous, recurring cancer characterized by a high rate of metastasis, poor prognosis, and lack of efficient therapies. KBU2046, a small molecule inhibitor, can inhibit cell motility in malignant tumors, including breast cancer. However, the specific targets and the corresponding mechanism of its function remain unclear. Methods: In this study, we employed (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H tetrazolium) (MTS) assay and transwell assay to investigate the impact of KBU2046 on the proliferation and migration of TNBC cells in vitro. RNA-Seq was used to explore the targets of KBU2046 that inhibit the motility of TNBC.… More >

Graphic Abstract

View

938

Download

162

Open Access

ARTICLE

YOUSEF KATIB^1,*, NASSER MULLA²
Oncology Research, Vol.32, No.11, pp. 1803-1809, 2024, DOI:10.32604/or.2024.052358 - 16 October 2024
Abstract Background: Lung cancer (LC) is one of the most common neoplastic diseases and a leading cause of death in Saudi Arabia. Its incidence in Saudi Arabia has increased by more than 3% within two decades. Our study aimed to describe the epidemiological and genetic landscapes of LC in Al-Madinah city in Saudi Arabia. Methods: A retrospective analysis was conducted on the medical records of 65 patients diagnosed with lung cancer between 2015 and 2021 at a single medical oncology center in Al-Madinah city of Saudi Arabia. Results: The mean patients’ age was 59.2 years, with 50… More >

View

635

Download

125

Open Access

RETRACTION

Oncology Research Editorial Office
Oncology Research, Vol.32, No.11, pp. 1811-1811, 2024, DOI:10.32604/or.2024.056887 - 16 October 2024
Abstract This article has no abstract. More >

View

264

Download

98

Open Access

RETRACTION

Oncology Research Editorial Office
Oncology Research, Vol.32, No.11, pp. 1813-1813, 2024, DOI:10.32604/or.2024.056888 - 16 October 2024
Abstract This article has no abstract. More >

View

278

Download

86

Open Access

RETRACTION

Oncology Research Editorial Office
Oncology Research, Vol.32, No.11, pp. 1815-1815, 2024, DOI:10.32604/or.2024.056890 - 16 October 2024
Abstract This article has no abstract. More >

View

240

Download

78

Open Access

RETRACTION

Oncology Research Editorial Office
Oncology Research, Vol.32, No.11, pp. 1817-1817, 2024, DOI:10.32604/or.2024.056892 - 16 October 2024
Abstract This article has no abstract. More >

View

270

Download

81

Open Access

RETRACTION

Oncology Research Editorial Office
Oncology Research, Vol.32, No.11, pp. 1819-1819, 2024, DOI:10.32604/or.2024.056893 - 16 October 2024
Abstract This article has no abstract. More >

View

280

Download

95

Open Access

RETRACTION

Oncology Research Editorial Office
Oncology Research, Vol.32, No.11, pp. 1821-1821, 2024, DOI:10.32604/or.2024.056895 - 16 October 2024
Abstract This article has no abstract. More >

View

231

Download

77

Open Access

RETRACTION

Oncology Research Editorial Office
Oncology Research, Vol.32, No.11, pp. 1823-1823, 2024, DOI:10.32604/or.2024.056896 - 16 October 2024
Abstract This article has no abstract. More >

View

247

Download

76

Open Access

RETRACTION

Oncology Research Editorial Office
Oncology Research, Vol.32, No.11, pp. 1825-1825, 2024, DOI:10.32604/or.2024.056897 - 16 October 2024
Abstract This article has no abstract. More >

View

249

Download

76

Open Access

RETRACTION

Oncology Research Editorial Office
Oncology Research, Vol.32, No.11, pp. 1827-1827, 2024, DOI:10.32604/or.2024.056902 - 16 October 2024
Abstract This article has no abstract. More >

View

258

Download

81

Open Access

RETRACTION

Oncology Research Editorial Office
Oncology Research, Vol.32, No.11, pp. 1829-1829, 2024, DOI:10.32604/or.2024.056904 - 16 October 2024
Abstract This article has no abstract. More >

View

333

Download

89